| 费湘平 陈立音 张腊娣.胸腺肽α1联合益气化痰法治疗老年慢性支气管炎迁延期的临床疗效观察[J].实用中西医结合临床,2015,15(8):3-4，89 |
| 胸腺肽α1联合益气化痰法治疗老年慢性支气管炎迁延期的临床疗效观察 |
| Clinical Effect Observation of Thymosin ?琢1 Combined with Yiqihuatan Method in Treating Elderly Patients with Chronic Bronchitis in Persisting |
| |
| DOI： |
| 中文关键词: 老年慢性支气管炎迁延期 益气化痰法 胸腺肽α1 临床疗效 |
| 英文关键词: Elderly patients with chronic bronchitis in persisting Yiqihuatan Method Thymosinα1 Clinical effect |
| 基金项目: |
|
| 摘要点击次数: 705 |
| 全文下载次数: 368 |
| 中文摘要: |
| 目的：观察胸腺肽α1联合益气化痰法治疗老年慢性支气管炎迁延期的临床疗效。方法：选取老年慢性支气管炎迁延期患者75例，随机分为对照组、中医治疗组以及联合治疗组，各25例，对照组采用西医常规治疗，在此基础上中医治疗组加用具有益气化痰功效的汤药治疗，联合治疗组在中医治疗组的基础上加用胸腺肽α1。结果：治疗后中医治疗组及联合治疗组的显效率和总有效率都明显高于对照组，P＜0.05；而联合治疗组的总有效率也高于中医治疗组，P＜0.05；但显效率无明显差异，P＞0.05。三组均未见严重的不良反应，无统计学差异，P＞0.05。治疗后，联合治疗组CD4+/CD8+较治疗前明显改善，P＜0.05；同时组间比较也有显著性差异，P＜0.05。结论：胸腺肽α1可以改善老年慢性支气管炎迁延期患者的细胞免疫功能，胸腺肽α1联合益气化痰法能够明显提高老年慢性支气管炎迁延期患者的临床疗效，而且无明显不良反应。 |
| 英文摘要: |
| Objective: To observe the effect of thymosinα1 combined with Yiqihuatan method in treating elderly patients with chronic bronchitis in persisting. Methods: The 75 elderly patients with chronic bronchitis in persisting were divided into control group, traditional chinese medicine (TCM) treatment group and combined treatment group, each group with 25 patients. The control group was treated with routine treatment of western medicine, the TCM treatment group was treated with decoction with the effect of Yiqihuatan and routine treatment of western medicine, and the combined treatment group was treated with thymosinα1 based on the treatment of TCM group. Results: After the treatment, the significant efficiency and total efficiency of the TCM treatment group and the combined treatment group was higher than that of the control group (P＜0.05); the total effective rate of the combined treatment group was also higher than that of the TCM treatment group (P＜0.05); but the significant efficiency had no significant difference (P＞0.05). The three groups had no serious adverse reactions (P＞0.05). After the treatment, the CD4+/CD8+ of the combined treatment group was significantly improved than before (P＜0.05), and compared with the other two groups, the combined treatment group had significant difference also (P＜0.05). Conclusion: Thymosinα1 can improve the cellular immune function in elderly patients with chronic bronchitis in persisting. Thymosin α1 combined with Yiqihuatan method can significantly improve the clinical efficacy of elderly patients with chronic bronchitis in persisting, without obvious adverse reaction. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
